Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK's Mission Banks £60m To Develop DUB Inhibitors

This article was originally published in Scrip

Executive Summary

UK fund manager Neil Woodford's investment trust has joined existing investors in a £60m fundraising by Mission Therapeutics, the UK drug discovery firm working to discover drugs targeting the ubiquitin pathway. The company was set up in 2011 by the management team of kuDOS Pharmaceuticals, which was bought in 2005 by AstraZeneca after it had conducted early development of the now approved ovarian cancer drug Lynparza (olaparib), an inhibitor of poly ADP ribose polymerase (PARP). Mission's scientific founder and chief scientific officer is Professor Steve Jackson, who founded KuDOS and who continues to carry out pioneering research into DNA damage repair at Cambridge University's Gurdon Institute.


Related Content





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts